Equities research analysts at Jones Trading began coverage on shares of Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) in a report released on Tuesday,Benzinga reports. The brokerage set a "buy" rating and a $45.00 price target on the stock. Jones Trading's price target indicates a potential upside of 60.14% from the company's previous close.
Several other equities research analysts also recently weighed in on the stock. Canaccord Genuity Group reissued a "buy" rating and set a $39.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. TD Cowen began coverage on Palvella Therapeutics in a report on Wednesday, February 5th. They issued a "buy" rating and a $44.00 target price for the company. Scotiabank began coverage on Palvella Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $38.00 price objective on shares of Palvella Therapeutics in a report on Tuesday, February 11th. Finally, Cantor Fitzgerald began coverage on Palvella Therapeutics in a research report on Wednesday, December 18th. They issued an "overweight" rating for the company. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $43.50.
Check Out Our Latest Report on PVLA
Palvella Therapeutics Trading Up 1.2 %
PVLA stock traded up $0.34 during trading on Tuesday, hitting $28.10. 74,902 shares of the stock traded hands, compared to its average volume of 62,262. The stock has a market capitalization of $315.31 million, a PE ratio of -2.32 and a beta of 0.54. Palvella Therapeutics has a 1 year low of $6.20 and a 1 year high of $29.27. The stock has a 50 day simple moving average of $20.24.
Institutional Trading of Palvella Therapeutics
Large investors have recently modified their holdings of the company. Suvretta Capital Management LLC purchased a new position in Palvella Therapeutics in the fourth quarter worth about $8,574,000. BVF Inc. IL bought a new position in shares of Palvella Therapeutics in the 4th quarter worth approximately $8,359,000. Samsara BioCapital LLC purchased a new position in shares of Palvella Therapeutics in the fourth quarter worth approximately $8,154,000. Frazier Life Sciences Management L.P. purchased a new position in shares of Palvella Therapeutics in the fourth quarter worth approximately $7,847,000. Finally, Adams Street Partners LLC bought a new stake in Palvella Therapeutics during the fourth quarter valued at approximately $4,916,000. Institutional investors own 40.11% of the company's stock.
About Palvella Therapeutics
(
Get Free Report)
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.
Read More
Before you consider Palvella Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palvella Therapeutics wasn't on the list.
While Palvella Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
